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AbstrACt
Introduction Depressive, anxiety and adjustment 
disorders are highly prevalent among mental health 
outpatients. The lack of funding for mental health 
problems produces inefficient results and a high burden 
of disease. New cost-effective group interventions 
aimed at treating these symptoms might be an 
appropriate solution to reduce the healthcare burden in 
mental health units. Mindfulness-based interventions 
(MBIs) have shown significant reductions in anxious, 
depressive and adjustment symptomatology. Recent 
research highlights the influence of compassion as a 
key mechanism of change. However, MBIs only address 
compassion implicitly, whereas compassion-based 
protocols consider it a core aspect of psychotherapy. 
In this randomised controlled trial, we hypothesise that 
the provision of attachment-based compassion therapy 
(ABCT), which is a compassion-based protocol, will be 
more effective than mindfulness-based stress reduction 
(MBSR), which is a conventional MBI programme, for 
the treatment of depressive, anxious and adaptive 
symptoms in patients in mental health settings.
Methods and analysis Approximately 90 patients 
suffering from depressive, anxious or adjustment 
disorders recruited from Spanish mental health settings 
will be randomised to receive 8 weekly 2 hours group 
sessions of ABCT, 8 weekly 2.5 hours group sessions 
of adapted MBSR (with no full-day silent retreat) or 
treatment as usual (TAU), with a 1:1:1 allocation rate. 
Patients in the ABCT and adapted MBSR groups will also 
receive TAU. The main outcome will be general affective 
distress measured by means of the ‘Depression Anxiety 
Stress Scales-21’ at post-test as primary endpoint. 
Other outcomes will be quality of life, mindfulness, self-
compassion and the use of healthcare services. There 
will be a 6-month follow-up assessment. Intention-
to-treat analysis will be conducted using linear mixed 
models. Per-protocol and secondary outcome analyses 
will be performed. A data monitoring committee 
comprising the trial manager, the ABCT and MBSR 
teachers and an independent clinical psychologist will 
monitor for possible negative side effects.
Ethics and dissemination Approval was obtained from 
the Ethics Committee of the General University Hospital 
of Castellón, Spain. The results will be submitted to 
peer-reviewed specialised journals, and brief reports will 
be sent to participants on request.
trial registration number NCT03425487
strengths and limitations of this study
 ► This study is the first to compare the effectiveness 
of an attachment-based compassion therapy (ABCT) 
group programme and a mindfulness-based stress 
reduction (adapted MBSR) group programme to 
treat depressive, anxious and adjustment symptoms 
in mental health settings.
 ► The inclusion of a suitable active control group 
and follow-up measurements will allow mediation 
analyses to assess potential mechanisms of im-
provement—such as mindfulness and self-com-
passion—that might function differentially in each 
meditation group.
 ► This pragmatic design includes a cost-effectiveness 
evaluation of both ABCT and adapted MBSR com-
pared with the treatment as usual that could assist 
decision-making processes to reduce the healthcare 
burden in Spanish mental health units.
 ► The main limitation of this study is that it will not be 
statistically powered to detect small size differenc-
es between the groups. However, it will serve as a 
guide for the planning of larger, more comprehen-
sive and more complex studies.
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IntroduCtIon
background and rationale
Depression is the most prevalent cause of disability and 
a major contributor to the disease burden worldwide.1 
Its prevalence has increased in recent years,2 with the 
number of people living with depression around the 
world estimated at 322 million in 2015, 4.4% of the global 
population.3 Between 2005 and 2015, the percentage of 
people suffering from depression increased by 18.4%. 
Depression is characterised by feelings of sadness, guilt, 
loss of interest or pleasure, low self-worth, disturbed 
sleep or appetite, tiredness and poor concentration.3 
These symptoms impair an individual’s ability to cope 
with daily life and are relevant determinants of quality 
of life and survival because at their most severe, they can 
lead to autolytic behaviours.4 5 It has been estimated that 
264 million people, 3.6% of the global population,3 suffer 
from a range of anxiety disorders. Again, this estimate 
is increasing owing to population growth and ageing 
processes. Anxiety refers to a group of mental disorders 
characterised by excessive worry and fear.6 The dura-
tion of symptoms typically experienced by people with 
anxiety makes it more of a chronic than episodic disorder, 
producing considerable impairment, decreased levels of 
health-related quality of life, greater healthcare utilisa-
tion and a considerable economic burden on society.7 8 
Comorbidity between depressive and anxious symptom-
atology is common and is related to higher role impair-
ment and symptom severity.9 10 Of patients diagnosed with 
major depression, 57.5% also met the criteria for at least 
one anxiety disorder,11 and 59.0% of individuals suffering 
from generalised anxiety disorder fulfil the criteria for 
major depression.12 Finally, adjustment disorder is a 
maladaptive reaction to an identifiable psychosocial 
stressor.13 It is among the most frequently diagnosed 
mental disorders,14–16 but data on its prevalence are 
limited. A multinational study, including Norway, Finland, 
Ireland and Spain, obtained a range in the general popu-
lation of 0.2%‒1%17; in primary care, the figure was 2.9% 
in Spain and 9.2% in Sweden.18 19 Adjustment disorder 
can be persistent over time, is usually presented with 
depressed mood or anxiety20 21 and has also been linked 
to suicidality.22
The consequences of these disorders are huge in terms 
of lost health. Given the high prevalence of these mental 
disorders and the low proportion of patients receiving 
evidence-based treatment, possibly due to educational, 
financial and organisational barriers,23 24 among others, it 
is essential that cost-effective interventions to treat these 
conditions become widely available.25 There is evidence 
that psychological treatments—specifically those framed 
within cognitive–behavioural therapy (CBT)—are effec-
tive in the treatment of depression, anxiety and adjust-
ment disorders, but they are expensive when individually 
supplied.26–28 Mindfulness-based interventions (MBIs) 
constitute a new group of psychological treatments that 
are immersed in the so-called ‘third wave’ CBTs.29 MBIs 
endeavour to train the mind to adopt a non-judgemental 
present-focused awareness by cultivating full attention 
through formal meditation, informal practices, psycho-
education and different introspective exercises. In 
general, meditation can be conceptualised as a set of 
attention-based, regulatory and self-inquiry training regi-
mens cultivated for various ends, including well-being 
and psychological health.30 There are different MBIs for 
the treatment of psychological disorders, although the 
two protocols with the greatest extension and evidence 
are mindfulness-based stress reduction (MBSR)31 and 
mindfulness-based cognitive therapy (MBCT).32 MBIs 
have demonstrated significant reductions in depressive, 
anxious and stress symptomatology,33 significant improve-
ments in quality of life, and a lower risk of relapses in 
depression.34 MBIs can show efficacy similar to that of the 
usual CBT programmes and even to that of pharmacolog-
ical treatments for anxiety and depression, with moderate 
effects when compared with waitlist controls but low 
effects when compared with other active treatments.28 35 
Doubts have also recently emerged in terms of their long-
term effect duration.36 37
Compassion meditation techniques are also classi-
fied under the ‘third wave’ psychotherapy umbrella.38 
Although the concept of compassion is very recent in 
psychology, there is an incipient line of research that 
highlights its influence on psychological well-being. In 
general, compassion forms a particular orientation of 
mind that is shaped in a motivational system orientated to 
certain sensitivity to suffering and a commitment to relieve 
suffering by recognising the universality of pain and the 
ability to meet that pain with equanimity.39 40 Compassion 
for the self (self-compassion) is this attitude focused on 
the self,41 and it has been found to be a key mechanism—
together with mindfulness abilities—in the effectiveness 
of techniques such as MBSR and MBCT.42 43 Authors have 
hypothesised that self-compassion could be the ‘crucial 
attitudinal factor’ in the relationship between mindful-
ness and mental health.44 However, this construct only 
works implicitly in the MBI protocols. A strong current 
of authors has recently been defending the need to work 
explicitly on compassion, considering it the real engine 
of change in MBIs. Currently, several protocols expressly 
focus on cultivating compassionate attitudes, for instance, 
the ‘Mindful Self-Compassion Programme’,45 with a 
general approach based on self-compassion skill building; 
‘Compassionate Mind Training’,46 with a general clinical 
approach and ‘attachment-based compassion therapy’ 
(ABCT),47 which can be adapted to the healthcare 
environment48 and is applicable to general and clinical 
populations.49 50 Moderate inverse relationships between 
self-compassion and depression, as well as anxiety and 
stress symptoms, have been observed,40 50 and compas-
sion programmes such as ABCT have produced large 
effect sizes (ESs) when treating depressive and anxious 
symptomatology in fibromyalgia patients, compared with 
active controls.51
If the self-compassion construct is at the very base 
of the effectiveness of MBIs when treating depressive, 
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anxiety and stress symptomatology, we could suppose 
that a specific compassion-based protocol might be 
more effective for treating people who suffer from those 
symptoms than a conventional MBI. No previous studies 
have directly compared specific compassion protocols 
such as ABCT with conventional MBIs such as MBSR, 
although previous research examining the outcomes of 
each group of programmes independently might suggest 
that explicitly teaching self-compassion to specifically 
increase self-compassion levels, as is done in the ABCT 
programme, would make a difference.42 49
objectives
The main aim of this study is to assess the effectiveness 
of ABCT added to treatment as usual (‘ABCT+TAU’), 
compared with MBSR added to TAU (‘MBSR +TAU’), in 
patients from mental health settings suffering from depres-
sive, anxiety or adjustment disorders. Secondary aims will 
be (1) to compare ‘MBSR +TAU’ and ‘ABCT+TAU’ with 
the ‘TAU alone’; (2) to analyse the possible mediating role 
of mindfulness and self-compassion on improvements in 
the ‘MBSR +TAU’ and ‘ABCT+TAU’ groups compared 
with ‘TAU alone’ and (3) to evaluate the cost-effective-
ness of both ‘MBSR +TAU’ and ‘ABCT+TAU’ groups 
compared with ‘TAU alone’.
The principal hypothesis is that ‘ABCT +TAU’ will be 
more effective than ‘MBSR +TAU’ for treating depressive, 
anxiety and adjustment disorders in patients in mental 
health settings. Secondary hypotheses are: (1) ‘MBSR 
+TAU’ and ‘ABCT +TAU’ will be more effective than 
‘TAU alone’ for treating depressive, anxiety and adjust-
ment disorders in patients in mental health settings; 
(2) mindfulness will be a mediator of the ‘MBSR +TAU’ 
programme improvements, whereas self-compassion will 
be a mediator of the corresponding ‘ABCT +TAU’ and 
(3) ‘ABCT +TAU’ will prove to be more cost-effective 
than ‘MBSR +TAU’, and both ABCT +TAU’ and ‘MBSR 
+TAU’ programmes will prove to be more cost-effective 
than TAU alone.
trial design
This study is a multicentre, randomised controlled trial 
(RCT) comprising three parallel arms, with pretreat-
ment, post-treatment and 6-month follow-up measure-
ments, and a 1:1:1 allocation rate among groups.52 
Patients from three mental health units in Castellón, 
Spain will be randomly assigned to three different 
parallel conditions, with two psychological interven-
tion groups (‘ABCT+TAU’ and ‘MBSR+TAU’) and the 
usual psychological/psychiatric treatment managed by 
their specialist (‘TAU alone’), to test the superiority of 
‘ABCT+TAU’ provision compared with ‘MBSR+TAU’, but 
also of ‘ABCT+TAU’ or ‘MBSR+TAU’ compared with the 
‘TAU alone’ provision. Those patients allocated to ‘TAU 
alone’ will be offered an adaptation of the mindfulness 
and compassion programmes after finishing the trial at 
the 6-month follow-up.
MEthods
This protocol was designed in accordance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials 2013 statement.53
study setting
Participants will be recruited from the mental health 
units of Illes Columbretes, Rafalafena and Cardenal Costa 
Healthcare Centres in Castellón, Spain. Psychiatrists or 
psychologists will be trained to use the Structured Clinical 
Interview for Diagnostic and Statistical Manual of Mental 
Disorders-Fifth Edition (DSM-5) Research Version54 as a 
semistructured guide for making DSM-5 diagnoses, ascer-
taining inclusion and exclusion criteria. When the clini-
cians at any of these mental health units detect a potential 
participant, he/she will be referred to the corresponding 
research unit to be offered the information about the 
study. It will be explained to the patients that only the 
research team will have access to their clinical history data 
and nobody outside of their health centre will be able to 
consult their medical records.
Eligibility criteria
The following inclusion and exclusion criteria will be 
applied when recruiting patients. Only patients meeting 
the inclusion criteria will be accepted into the study.
Inclusion criteria
 ► Age: between 18 and 75 years.
 ► Depressive and/or anxious disorder, or adjustment 
disorder with depressive and/or anxious symptom-
atology, according to clinical criteria based on the 
DSM-5.
 ► Disorder of mild or moderate severity according to 
clinical criteria (based on DSM-5).
 ► Understanding of spoken and written Spanish.
 ► Provision of written informed consent.
Exclusion criteria
 ► Having done any type of meditative/contemplative 
practice in the previous year.
 ► The diagnosis of any disease that can affect the central 
nervous system (eg, brain pathology, traumatic brain 
injury and dementia).
 ► Other psychiatric diagnoses or acute psychiatric 
illness (eg, substance dependence or abuse, history 
of schizophrenia or other psychotic disorders, eating 
disorders)
 ► Any medical condition or infectious or degenerative 
disease that can affect mood.
 ► Presence of delusional ideas or hallucinations, 
whether or not consistent with mood and suicide risk.
Once informed, candidates will be asked whether they 
wish to participate in the study. If they accept, they will 
subsequently be provided with the confidentiality and 
informed consent documents. Those who do not accept 
will continue with their usual treatment at their health 
centre.
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Patient and public involvement
Although importance is being given to engaging stake-
holders in the choice of research question,55 no patients 
or members of the public were directly involved in the 
development of the research question in this case because 
of the novelty and incipient use of the ABCT protocol. 
However, prior to the recruitment stage, a group of advi-
sory patients who were contacted through the Depressive 
Disorders Association of Aragon were interviewed at the 
mental health units about the research question as well 
as the design and feasibility of the interventions. These 
advisers agreed with the relevance of the study question 
but they proposed that the initially planned day retreat 
session, included in the MBSR programme, should be 
ruled out because of likely schedule incompatibilities. 
All of this was corroborated by study patients, who were 
specifically asked for their schedule preference and the 
possibility of including a day retreat session. Advantage 
was taken of this to adjust the design in order to balance 
the intensity of both ABCT and MBSR interventions. 
Study patients were only directly involved in this part of 
the design. No patients or members of the public will 
be engaged in recruitment, conducting and outcome 
measurement, over which the research group will have 
full control, although an independent advisory reference 
group will be put together and meet three times during 
the course of the study to receive updates from the study 
researchers. These meetings will serve to review the study 
development, and the data monitoring committee (DMC) 
will be informed of possible comments and suggestions. 
Study results will be disseminated to participants by email, 
including a brief personal and comprehensive report on 
request. The burden of the interventions included in 
this study will be not assessed by patients, but they will 
provide data on the use of healthcare and social services 
and other economic information.
Interventions
Patients in all conditions will be informed that they will 
continue to receive the services as usual before enrolment 
in the study, so that all participants regardless of the arm to 
which they are assigned will receive their corresponding 
TAU. To be consistent with the pragmatic nature of the 
study, care will be taken not to interfere with routine prac-
tices for intervention delivery. Thus, ad hoc adherence 
optimisation procedures will not be used. Patients will 
be informed in the first interview that they will be free 
to decide whether to discontinue or modify their allo-
cated intervention, on request, in response to possible 
harm, adverse events or improving/worsening symp-
toms, without affecting their ability to continue to receive 
their usual treatment. Antidepressant and/or anxiolytic 
medication use would be permitted if the participant 
agreed not to modify the pharmacological treatment 
that was prescribed during the study period (it would be 
established that the treatment could be decreased but 
not increased). No other different psychological and 
meditative treatments outside of usual treatment will be 
permitted to be received during the study period.
Attachment-based compassion therapy
Subjects assigned to the ABCT intervention arm will 
receive 8 weekly 2 hours group sessions conducted by a 
clinical psychologist certified in ABCT and specifically 
trained to ensure the integrity of the ABCT intervention, 
following its specific content and avoiding overlapping 
with other psychotherapeutic techniques. Group sizes 
can range from 10 to 15 participants. All sessions will be 
taught by the same psychologist following a standardised 
protocol48 to maintain consistency with the programme. 
The ABCT protocol includes teachings, daily simple exer-
cises, meditation, visualisations and specific practices to 
augment the patients’ ability to be considerate and kind 
towards themselves and their own experience (more 
specifically their experience of suffering), and others’ 
experience of suffering. ABCT is based on attachment 
theory,56 which provides a framework for understanding 
the links between close relationships and psychopa-
thology. Subjects will receive written and audio mate-
rials and resources with theoretical concepts, exercises 
and meditation guides to support home practice. Home 
exercises will be commented on in each session in order 
to resolve possible doubts and encourage adherence to 
the programme. Table 1 shows the session structuring in 
terms of theory and formal and informal practices.
Mindfulness-based stress reduction
Subjects assigned to the MBSR intervention arm will 
receive 8 weekly 2.5 hours group sessions conducted by 
a clinical psychologist certified in MBSR therapy and 
specifically trained to ensure the integrity of the MBSR 
programme, following its specific content and avoiding 
overlapping with other psychotherapeutic techniques. 
Group sizes will range from 10 to 15 participants. All 
sessions will be taught by the same psychologist following 
the standardised MBSR authorised curriculum guide31 57 
to reinforce consistency with the original programme. 
The MBSR protocol presents an educational orienta-
tion that includes teachings, informal exercises, formal 
meditation (eg, sitting meditation, body scan, walking 
meditation and gentle yoga), as well as individual and 
group dialogues and inquiries about perceptions, habits 
and patterns that may interfere with learning. However, 
the practice of meditation exercises during a full day of 
retreat included in the original protocol will be ruled out 
to avoid schedule incompatibility, and thus a workable 
modification will be established. This same adjustment has 
also been done in other previous MBSR adaptations.58 59 
No other major modifications will be made to the form 
or content, instructor characteristics or intention of the 
programme.60 As in the previous intervention, subjects 
will receive written and audio resources with theoretical 
concepts, exercises and meditation guides to support 
home practice. Home exercises will be commented on in 
each session to resolve doubts and encourage adherence. 
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Table 1 Theory, formal and informal practice content of the ABCT programme
Session 1:
Preparing ourselves for 
compassion. Kind attention
Theory: The workings of our brain; the reality of suffering: primary and 
secondary suffering; what is and is not compassion?
Formal practice: Compassionate breathing and compassionate body scan; 
compassionate coping with difficulties
Informal practice: 3 min compassionate practice; self-compassion diary; 
savouring and giving thanks
Session 2: Discovering our compassionate 
world
Theory: Compassion and mindfulness; self-esteem and compassion; fear of 
compassion
Formal practice: The figure of affect: connecting with basic affection; 
developing a safe place; The compassionate action; Identifying the figure of 
secure attachment
Informal practice: The object that joins us to the world; diary of compassion 
practice; what are we good at?
Session 3: Developing our compassionate 
world
Theory: How compassion acts; effectiveness of compassion; self-criticism
Formal practice: Developing the figure of secure attachment; developing the 
compassionate voice
Informal practice: Writing a letter to a compassionate friend
Session 4: Understanding our 
relationships with compassion
Theory: Attachment styles; importance of these styles in everyday life
Formal practice: Becoming aware of our attachment style; ability to receive 
affection: friend, indifferent person, enemy
Informal practice: Letter to your parents
Session 5: Working on ourselves Theory: Importance of affection towards ourselves and others
Formal practice: Showing affection to friends and indifferent people; showing 
affection to ourselves; reconciliation with our parents; three positive aspects 
and three negative aspects of our parents
Informal practice: The greatest display of affection (in general and from our 
parents); the illusion of labels
Session 6: Advanced compassion (I): 
forgiveness
Theory: Guilt and the importance of forgiveness
Formal practice: Forgiving yourself; asking others for forgiveness; forgiving 
others and showing compassion to enemies; showing forgiveness for the hurt 
caused by loved ones (only for people with this experience); recapitulation
Informal practice: Compassion in everyday life; interdependence
Session 7: Advanced compassion 
(II): becoming your own 
attachment figure and handling 
difficult relationships
Theory: Working in three periods; Envy; usefulness of being our attachment 
figure; difficult people
Formal practice: Working with envy; becoming our own attachment figure; 
handling difficult relationships
Informal practice: Not taking anything personally; looking others in the eye and 
connecting with their suffering
Session 8: Beyond compassion: 
equanimity
Theory: Equanimity; How to keep up the practice of compassion for a lifetime
Formal practice: Equanimity (I): We are all equal; Equanimity (II): The illusion of 
categories; Equanimity (III): Showing the world the gratitude we have not been 
able to give back
Informal practice: Our values and their relationship with compassion; The 
cosmic attachment figure; The tantric embrace
ABCT, attachment-based compassion therapy.
The theory, practice and support contents that form the 
structuring of the sessions are described in table 2.
Treatment as usual
TAU is delivered in current daily practice by psychiatrists 
and clinical psychologists of the national mental health 
service in Spain. TAU can refer to psychiatric treatment, 
which typically includes prescription and monitoring of 
antidepressant and/or anxiolytic medication, psycho-
logical treatment (possibly including case management, 
CBT techniques, empathic listening and/or supportive 
counselling), or a combination of both treatments. 
Frequency of visits will vary depending on the type of treat-
ment received and the severity of the case, but patients’ 
visits to their specialist are typically scheduled at intervals 
of at least 1 month.
outcomes
Several outcomes will be assessed and compared 
between the psychotherapy arms and the ‘TAU alone’ 
condition to evaluate the effects and cost-effectiveness 
of the programmes. Following the tripartite model of 
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Table 2 Theory, practice and support contents of the adapted MBSR programme
Session 1:
Introduction: What is 
Mindfulness and MBSR?
Theory: When we are breathing, there are more positive things than negative 
things inside us, whatever the problems we must face; formal and informal 
meditation
Practice: Attention to breathing here and now; body exploration meditation
support: raisin meditation.
Session 2: Body awareness and 
perception
Theory: What glasses are we wearing? How we see and interpret situations 
determines how we respond to them; perception and conditioned patterns
Practice: breathing meditation/yoga
Support: 9 dots exercise
Session 3: Get out of autopilot and be in 
the present
Theory: We are on the path of consciousness; doing mode versus being mode; 
thoughts (introduction)
Practice: sounds meditation
Support: diary of pleasant events
Session 4: Thoughts, emotions and stress Theory: Curiously investigate reactive patterns; stress physiology: sympathetic/
parasympathetic system; physiology of emotions
Practice: name emotions/allow emotions
Support: diary of unpleasant events
Session 5: Acceptance Theory: Midpoint of the course: renewing the commitment; opening a space 
between the stimulus and the reaction; mechanisms of coping with stress
Practice: standing and walking meditation/attention in open focus
Support: response versus reaction exercise
Session 6: Interpersonal relationships/
letting go of difficult situations
Theory: Judgement, comparison and presumptions; The alteration produced by 
conflicting communication; letting go of difficult situations (ruminations)
Practice: Meditation on letting go of difficult situations/aikido
Support: active listening exercise; diary of difficult or stressful conversations
Session 7: Integrate the practice of 
Mindfulness in everyday life
Theory: Self-care; reflection on nutritive and adaptive lifestyles versus 
maladaptive, self-limiting and self-destructive; become aware of our values; How 
I position myself before what happens to me according to my values
Practice: Metta Meditation. Loving kindness
Support: Exercise of conscience: why am I here?
Session 8: Renew our intention, self-care 
and self-compassion
Theory: Self-care and how to grow it; Collective wisdom: what have we learnt, 
from ourselves, from others? We are different now with respect to when we 
arrived.
Practice: Meditation Cultivating Self Compassion; Mountain Meditation
Support: Dyadic exercise: who I am? Why I am here? Where do I want to go?
MBSR, mindfulness-based stress reduction.
Table 3 Study outcomes
Outcome Area Source Variable type Time
DASS-21 General affective distress Self-reported Treated as interval Baseline, post-treatment and follow-up
EQ-5D Health-related quality of life Self-reported Treated as interval Baseline, post-treatment and follow-up
FFMQ Facets of mindfulness Self-reported Treated as interval Baseline, post-treatment and follow-up
SCS Facets of self-compassion Self-reported Treated as interval Baseline, post-treatment and follow-up
CSRI Health and social services use Self-reported Treated as interval Baseline and follow-up
CSRI, Client Service Receipt Inventory; DASS-21, Depression Anxiety Stress Scales; EQ-5D, European Quality of Life Scale-5 Dimensions; 
FFMQ, Five Facet Mindfulness Questionnaire; SCS, Self-Compassion Scale.
anxiety, depression and distress, which suggests that 
both anxiety and depression conditions have in common 
several symptoms of negative emotional states,61 the 
primary outcome will be a self-reported global measure 
of general affective distress to provide data on interven-
tion effectiveness. Secondary outcomes will permit the 
development of a more detailed exploration into how 
psychotherapy arms work in terms of health-related 
quality of life, and mindfulness and self-compassion 
as possible mediators of psychotherapy effects, as well 
as the use of healthcare and social services associated 
with conditions. Assessors will be specifically trained to 
administer all the referred instruments. Outcomes are 
summarised in table 3.
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Main outcome
The main effectiveness outcome will be general affective 
distress, which will be assessed through the brief version 
of the ‘Depression Anxiety Stress Scales-21’ (DASS-21).62 
The DASS-21 is a self-report questionnaire composed 
of the three negative affectivity subscales of depression, 
anxiety and stress. Each subscale is made up of seven 
items, and each item comprises a statement and four 
Likert-type response options to reflect severity (rated 
from 0 ‘did not apply to me at all’ to 3 ‘applied to me very 
much, or most of the time’). To yield equivalence with 
the long DASS-42 version, the total score of each subscale 
is doubled.62 In addition, this questionnaire provides 
us with a one-dimensional global measure of emotional 
distress which will be considered the main study outcome. 
It comprises all 21 items configuring a general factor, and 
it will be used as a continuous dimensional variable that 
ranges from 0 to 126. Participants are asked to indicate 
how much each statement applied to them over the past 
week. The DASS-21 has been specifically validated in the 
Spanish population, showing strong indices of internal 
consistency (total scale α=0.96; depression α=0.93; 
anxiety α=0.86 and stress α=0.91) and expected patterns 
of discriminant, convergent and factorial validity.63
Secondary outcomes
A general health-related quality-of-life measurement will 
be performed to compare possible differences between 
treatments. The ‘European Quality of Life Scale-5 
Dimensions’ (EQ-5D)64 will be used. The EQ-5D is a stan-
dardised instrument to measure quality of life that has 
been applied to a wide range of health conditions and 
treatments, and provides a simple descriptive profile and 
a single index value for general health status. It includes 
information about mobility, personal care, daily activities, 
pain/discomfort, anxiety/depression and a personal esti-
mate of the present general health state compared with 
the previous 12 months, all of them rated on a Likert-
type scale with three response options. In addition, this 
questionnaire includes a visual analogue scale (VAS) to 
measure present health state, with all the possible values 
ranging from 0 to 100. The Spanish version of the EQ-5D 
will be used.65 The ability of the descriptive system and 
the VAS of the Spanish version of the EQ-5D to discrimi-
nate between healthy individuals and critical and chronic 
patients has been observed to be good.
As previously mentioned, mindfulness and self-com-
passion have been presented as possible mechanisms 
underlying the therapeutic effects of meditative inter-
ventions.42 43 Thus, to evaluate their possible differen-
tial mediation effect between treatments, they will be 
measured using the ‘Five Facet Mindfulness Question-
naire’ (FFMQ)66 and the ‘Self-Compassion Scale’ (SCS).67 
The FFMQ is a 39-item self-report measure of mindful-
ness. It comprises five facets: observing, describing, acting 
with awareness, non-judging of inner experience and 
non-reactivity to inner experience. Respondents indi-
cate on a 5-point Likert-type scale the degree to which 
each item is true for them (ranging from 1 ‘never or very 
rarely true’ to 5 ‘very often or always true’). Higher scores 
reflect higher levels of mindfulness. The facet scores 
can be combined to produce a total mindfulness score 
that ranges from 39 to 195. The Spanish version of the 
FFMQ68 has shown good psychometric properties, with 
Cronbach’s alpha values between 0.80 and 0.91 on all 
the subscales. On the other hand, the SCS is a 26-item 
questionnaire designed to assess the components of 
self-compassion across the facets of common humanity, 
mindfulness and self-kindness. The SCS uses a 5-point 
Likert-type scale, ranging from 1 (‘almost never’) to 5 
(‘almost always’). Higher scores indicate higher levels 
of self-compassion. Although the construct was defined 
using three facets, factor analysis suggests six subscales, 
which represent the positive and negative aspects of each 
facet as follows: self-kindness, self-judgement, common 
humanity, isolation, mindfulness and overidentification. 
The subscale scores can be combined to produce a total 
self-compassion score69 that ranges between 26 and 130. 
The Spanish version of the SCS70 is a valid and reliable 
instrument, with internal consistency values α≥0.72, and 
test–retest reliability values ≥0.81 on all the subscales.
The possible differential use of healthcare and social 
services and other economic effects (eg, time corre-
sponding to sickness absence) between treatments will be 
evaluated by means of the ‘Client Service Receipt Inven-
tory’ (CSRI)71 questionnaire. The version of the CSRI 
questionnaire to be used in this study has been designed 
to collect retrospective data on service utilisation in the 8 
months prior to baseline assessment and in the 8 months 
prior to follow-up measurement. The Spanish-validated 
version of the CSRI will be used.72
In addition to the previously mentioned outcomes, the 
following sociodemographic data will be collected at base-
line to describe and compare the general characteristics 
of participants included in the different study arms: age, 
gender, marital status (single, married/relationship, sepa-
rated/divorced, widowed), number of children, place 
of residence (own home, relative’s home, neighbour’s/
friend’s home, residential facility or other), education 
(no studies, primary studies, secondary studies, univer-
sity studies or other), employment (unemployed, tempo-
rary contract, permanent contract, self-employed, home 
duties, student, benefit recipient or retired), economic 
level (<national minimum wage (NMW) or NMW, 1–2 x 
NMW, 2–4 x NMW or >4 x NMW).
All the baseline information concerning outcomes 
(table 3) and sociodemographic variables will be collected 
before randomisation. Data on attendance at MBSR 
and ABCT groups will be recorded. Moreover, partici-
pants in meditation groups will be asked at the post-test 
about the number of weekly meditation practice days, 
the number of minutes of meditation on each practice 
day, and what they have learnt and taken from the group 
(as an open question to be completed in approximately 
three lines). All the participants will provide post-treat-
ment data about mental healthcare (continues TAU, 
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Figure 1 Partcipant timeline. TAU, treatment as usual.
abandons TAU, discharged, other) and possible changes 
in pharmacological treatment in the previous 2 months 
(no change, reduced medication, increased medication, 
change of medication). Finally, participants in medita-
tion groups will be asked again at the 6-month follow-up 
about the number of weekly meditation practice days and 
the number of minutes of meditation on each practice 
day. At follow-up, all participants will also provide data 
about mental healthcare (continues TAU, abandons 
TAU, discharged, other), and possible changes in phar-
macological treatment in the last 6 months (no change, 
reduced medication, increased medication and change 
of medication).
sample size
Sample size has been estimated considering the main 
hypothesis (‘ABCT+TAU’ will be more effective than 
‘MBSR +TAU’ for treating depressive, anxiety or adjust-
ment disorders). There are no references on previous 
direct comparisons between ABCT and MBSR groups, so 
we will perform an exploration in this respect. According 
to the literature and considering the TAU active control 
comparator used, we assume a large effect of ABCT and a 
small effect of MBSR in the primary outcome of general 
affective distress.28 36 51 73 Therefore, with an equal 1:1:1 
allocation rate, supposing a large difference between 
ABCT and MBSR conditions, with an ES of roughly 
d=0.80, accepting an alpha of 0.05 and a beta risk <0.2 in a 
bilateral contrast, we will need approximately 75 patients: 
25 in the MBSR condition, 25 in the ABCT group and 25 
in the TAU condition. Assuming a patient attrition rate 
at follow-up of approximately 15%–20%, the total sample 
size needed will be established at 90 patients (30 in each 
group).
recruitment
Recruitment will be conducted consecutively in one 
wave from September 2018 until the target sample size is 
completed (patient recruitment is expected to be final-
ised in February 2019). Figure 1 shows the participant 
timeline overview and figure 2 is a more detailed study 
flow chart showing recruitment through to data collec-
tion and results. We met with the psychologists and 
psychiatrists responsible for three mental health units in 
Castellón and gave them verbal and detailed written infor-
mation about the study and about the selection criteria of 
the potential participants. Having agreed to collaborate 
with us, they will oversee the informing of patients who 
meet the established selection criteria and the referring 
of those patients who agree to participate to the research 
group assessors at the corresponding mental health unit.
After an (approximately 1 hour) individual interview 
with the patients to inform them about the study, in which 
they are also told about the importance of commitment in 
these types of interventions, all those who agree to partic-
ipate, provide written informed consent and complete 
the baseline assessment, will be included in order to be 
randomised. During this interview, patients will be able 
to ask questions on possible doubts about any aspect of 
the study, which will be answered by the assessors. None-
theless, all participants must agree to their inclusion in 
the study prior to randomisation, and they will not be 
informed of their group allocation until after completion 
of the baseline measurements.
randomisation and blinding
A simple random sequence will be remotely generated 
after baseline evaluation by a member of the research 
group who is not involved in the study and has no 
knowledge of the study aims, using computer-generated 
random sequence numbers with a 1:1:1 allocation rate. 
Participants will be informed by telephone of the exper-
imental condition to which they have been randomly 
assigned, that is, to ‘ABCT+TAU’, ‘MBSR +TAU’ or ‘TAU 
alone’. The numeric random sequence document will 
be unavailable to the researcher in charge of enrolling 
and assessing participants, in order to avoid predict-
ability. He will be unaware of the treatment group to 
which any patient belongs and will be advised not to 
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Figure 2 Study flow.
ask for this information. The psychologists and psychi-
atrists providing TAU will also be unaware, for as long 
as possible, of the arm to which the patient has been 
randomised. Patients will be requested to not discuss the 
intervention they are receiving with their corresponding 
clinicians. Participants and group instructors cannot be 
blind to arm allocation because of the nature of the inter-
ventions, which are based on psychotherapeutic content 
that can be identifiable—although all the study arms will 
configure active groups of treatment. However, primary 
analysis will be conducted by a statistician who will receive 
the database blind to which arm comprises each inter-
vention, and to any other sociodemographic information 
that might facilitate identification of the intervention 
group. The groups to which participants are allocated 
may only be unblinded to the trial manager in the event 
of reported adverse events or other unintended effects of 
interventions or trial conduct.
Inducements for participation
Participants will not receive any remuneration for taking 
part in the study, and there will be no inducements for 
completing the interventions beyond their suffering from 
depression, anxiety or adjustment disorders that must be 
treated. However, through the individual interview prior 
to randomisation, participants will be strongly advised of 
the importance of engagement in their corresponding 
programmes and practices so that the interventions are 
able to work and thus to be relieved of their symptoms. 
Moreover, regular motivational techniques to increase 
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adherence of participants to sessions and daily tasks are 
included in the own programmes—for example, daily 
tasks aids, such as compassion or mindfulness medita-
tion audio recordings (depending on the condition) will 
be provided in each group, and all participants will be 
encouraged to do a daily task at home and will be asked 
to keep a daily written record of the number/duration 
of practice sessions. To promote participant retention 
and completion of the assessment, those participants who 
complete all the measurement waves will be given the 
opportunity on completion of the trial to receive informa-
tion concerning the evolution of their affective distress 
scores throughout the study, and to receive a final report 
on request.
data management
To ensure the quality of the data, assessors will be specif-
ically trained and the transcription processes from the 
paper and pencil surveys to the electronic data sheets will 
be performed twice by two independent researchers, while 
a third person will integrate them by revising the orig-
inal source in case of discrepancy. This third researcher 
will also perform range checks for data values. Only elec-
tronic data will be used for the study. The data will be 
treated anonymously and will be stored on a computer 
server at the research group’s headquarters; paper and 
pencil questionnaires will be kept under lock and key in a 
filing cabinet at the research group’s headquarters. Data 
from outcome measurements will be separated from any 
identifying information, and advanced encryption stan-
dard strategies concerning data encryption and use of 
personal passwords will be implemented to the database 
to guarantee protection of personal information.
Analysis plan
Sociodemographic and outcome descriptive data at base-
line will be analysed by means of frequencies (percent-
ages), medians (IQR) and means (SD) according to their 
level of measurement and statistical distribution. The 
three treatment conditions will be compared with eval-
uate the success of randomisation, including diagnosis, by 
using the χ2 or Fisher’s exact test for qualitative variables, 
and Kruskal-Wallis or one-way analysis of variance tests 
depending on the shape of the distributions of outcome 
measures.
Clinical effectiveness
Reporting of this RCT will follow the recommended 
Consolidated Standards of Reporting Trials guide-
lines.74 75 Primary analysis will consist of a comparison 
between ‘ABCT+TAU’ and ‘MBSR +TAU’ arms at post-test 
as primary endpoint, adjusted for those routine sociode-
mographic variables that could be unbalanced at base-
line, and considering the main outcome DAAS-21 total 
score as a continuous variable. Analysis will be performed 
using a repeated measures design with an intention-to-
treat base and linear mixed-effects regression. Subjects 
will be introduced in the random part of the model by 
means of the restricted maximum likelihood method, 
which produces unbiased estimates of variance and 
covariance parameters when using small sample sizes or 
unbalanced data.76 The ‘treatment by time’ interaction 
will be specifically considered to assess the trajectories 
throughout the study and to determine whether possible 
differences between arms will be consistent over time. 
Raw estimations of slope coefficients (and their 95% CI) 
will be calculated. Cohen’s d statistic, as an ES measure of 
between-group differences, will be calculated by means 
of pooled pretest SDs to weight the differences in the 
pre–post marginal means—using SEs to derive SD and 
considering the size of the groups.77 ES values of d=0.20 
are considered small, with 0.50 medium and 0.80 large.78 
In addition, marginal R2 values (only considering the 
variance of the fixed effects) and conditional R2 values 
(considering both the fixed and the random effects) will 
be calculated.79
Secondary analysis will evaluate the maintenance of 
the improvements achieved at 6-month follow-up. More-
over, other secondary analyses will explore the clinical 
significance of improvements using the Jacobson and 
Truax method80 to establish both the cut-off point and 
reliable change index on the DAAS-21 total score. This 
criterion of classification will be used to calculate abso-
lute risk reduction and number needed to treat (NNT); 
a 95% CI for each NNT will be calculated. We will also 
explore results of the subscales of the DAAS-21 and 
the secondary outcomes of EQ-5D, FFMQ and SCS—
considering total scores and subscales—using the same 
analytical strategy used for the primary analysis. Sensi-
tivity analysis will be performed to assess the effects of 
missing data, which will be replaced by multiple impu-
tations based on chained equations and will include the 
main and secondary outcomes at all the waves—as well 
as routinely collected sociodemographic data—as long 
as there are <40% missing data in the corresponding 
outcomes to ensure validity, and whether missing values 
are distributed at random(MAR).81 A per-protocol anal-
ysis will also be conducted, considering the criterion 
of ≥50% attendance of sessions as the minimum dose 
assumed to reach programme compliance.43 82 We will 
also perform a parallel evaluation of the effect for each 
session attended separately. Predefined subgroup anal-
yses will also be performed on the primary outcome 
using interaction tests83 by (1) baseline DAAS-21—those 
patients that are initially worse might drive change; (2) 
symptomatology (eg, depression, anxiety, mixed and 
adjustment disorder)—some programmes could func-
tion better with specific diagnoses and (3) amount of 
home practice—one might expect that the more home 
practice, the greater the benefits. Multilevel models will 
also be used to assess the non-specific, that is, common, 
ingredients of MBSR and ABCT compared with TAU by 
adding the treatment group in the mixed model random 
part and to assess their transdiagnostic effectiveness by 
including the diagnosis group in this part.
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Mediation analyses
The potential role of mindfulness and self-compassion 
as possible mediators of changes will be explored on the 
primary and secondary outcomes. For this purpose, (1) 
primary and secondary outcome prefollow-up differential 
scores will be calculated and considered dependent vari-
ables; (2) pre–post differential scores of mindfulness and 
self-compassion total scores—as two measures composed 
by the sum of their corresponding facets—will be calcu-
lated and included in the same model as parallel process 
variables; (3) the group condition (with two independent 
possibilities: ‘ABCT+TAU’ vs ‘TAU alone’ or ‘MBSR+TAU’ 
vs ‘TAU alone’) will be considered the independent vari-
able. The mediating analyses will be conducted using 
maximum likelihood-based path analyses for continuous 
dependent variables. Regression coefficients of boot-
strapped indirect effects will be estimated, as well as their 
95% CIs based on 10 000 bootstrap samples, considering a 
significant mediating effect when the referenced 95% CI 
does not include zero.84 Total or partial mediation will 
be established by calculating the percentage of the total 
mediating effects and the percentage of each mediator 
independently.
Cost analyses
The economic evaluation of this study will follow the 
guidelines for conducting pharmacoeconomic analyses in 
the Spanish context, the Consolidated Health Economic 
Evaluation Reporting Standards,85 as well as the guide-
lines set by the International Society for Pharmacoeco-
nomics and Outcomes Research.86
Cost will be estimated from the healthcare and soci-
etal perspectives for the 8 months prior to baseline and 
during the 8 months prior to follow-up. The cost derived 
from pharmacological therapy, medical tests and the use 
of health-related services will be added to calculate direct 
healthcare costs using the unit costs of the corresponding 
financial year in €. The cost of medication will be calcu-
lated by determining the price per mg according to the 
information of the drug from the Spanish Ministry of 
Health, Consumer Affairs and Social Welfare, including 
value-added tax. Total costs will be estimated by multi-
plying the mg price by the daily dosage in mg and the 
number of days of treatment. The unit cost data for 
medical tests and health services will be obtained from 
the OBLIKUE database of healthcare costs.87 Indirect 
costs (eg, lost productivity) will be estimated using the 
human capital approach that involves multiplying the 
minimum daily wage in Spain for the corresponding year 
by the number of sickness absence days. Finally, total costs 
will be calculated by summing direct and indirect costs 
and will be expressed in €.
The effectiveness of the interventions will be estimated 
by means of the difference between the DAAS-21 score 
at baseline and at follow-up, and utility will be estimated 
using quality-adjusted life-years (QALYs) at follow-up. 
Cost-effectiveness will be analysed through the estimation 
of incremental cost-effectiveness ratios (ICERs) for the 
intervention groups of ‘ABCT+TAU’ and ‘MBSR +TAU’, 
with ‘TAU alone’ considered a control group. ICER is 
the ratio between incremental costs and incremental 
effectiveness and is calculated as ‘cost active intervention 
group—cost control intervention group/utility active 
intervention group—utility control intervention group’. 
In addition, to provide an estimation of the extra costs 
that are needed to gain one responder with clinical signif-
icance in ‘ABCT+TAU’ and in ‘MBSR+TAU’ compared 
with ‘TAU alone’, we will perform cost-effectiveness 
analysis considering a dichotomous treatment response 
outcome based on the Jacobson and Truax classification 
criterion referenced above.80 Cost–utility will be anal-
ysed through the estimation of incremental cost–utility 
ratios (ICURs) as the ratios between incremental costs 
and incremental utilities measured in QALYs. QALYs will 
be estimated using the area-under-the-curve technique. 
ICURs will be estimated using the same equation but 
employing QALYs instead of clinical units.
Two cost–utility planes will be plotted, one for each 
contrast (‘MBSR+TAU’ vs ‘TAU alone’ and ‘ABCT+TAU’ 
vs ‘TAU alone’). In each cost–utility plane, the incre-
mental costs between the corresponding intervention 
group and the ‘TAU alone’ group will be plotted on the 
y-axis, and the incremental utility will be plotted on the 
x-axis.
Level of significance
The overall alpha level will be set at 0.05. No corrections 
for multiple comparisons will be made for the primary 
analysis—because only one contrast will be made in this 
regard, that is, ‘ABCT +TAU’ vs ‘MBSR +TAU’ at post-test 
as primary endpoint—and for the secondary analyses—
because they will be considered explorative in the general 
context of the present study.88
Statistical analysis plan
A statistical analysis plan (SAP), including a comprehen-
sive and detailed description of the methods and presen-
tation of data analysis, will be developed during the course 
of the study. The SAP will be finalised by a designated stat-
istician (JM-M) with appropriate qualifications and expe-
rience, and will be revised by all the study team members 
prior to the database lock for use in the final statistical 
analysis. Any discrepancies or changes made between the 
analysis plan in the present protocol and final SAP will be 
explained in the SAP document.
Monitoring and safety
Participation in meditation programmes, even without 
intensive retreats, could cause or exacerbate nega-
tive experiences at rates similar to those occurring in 
psychotherapy.89 90 Such negative side effects might carry 
serious adverse events (eg, psychosis, mania or suicidal 
ideation)91 92 which, although very infrequent, must be 
adequately monitored. Therefore, study participants 
will be requested to report to the psychologist teachers 
in charge of the groups any sign of deteriorating mental 
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or physical health (serious or otherwise) that might arise 
during the sessions, with special emphasis on possible 
uncomfortable moments during the exercises and 
distressing thoughts coming into their minds.93 Partici-
pants will also be requested to notify the occurrence of 
such experiences taking place in the period between 
sessions and/or visits, or any other circumstances that 
could lead to their consideration of withdrawing from 
the study. In addition, a checklist will be used to track 
adverse events during the interventions in order to 
monitor general potential adverse events such as head-
aches, dizziness and sleep problems or difficulties across 
the interventions.
A DMC will be set up, comprising a psychiatrist trial 
manager, the psychologist teachers in charge of the 
groups and an independent clinical psychologist familia-
rised with the management of patients with depressive, 
anxiety and adjustment disorders. In principle, the DMC 
will meet three times throughout the trial—after the 
baseline, post-treatment and follow-up measurements—
but will be available on request at any time to provide 
support and information to all parties where necessary. 
The study team will monitor the depression, anxiety and 
stress independent subscales of the DASS-21 each time 
it is completed by patients and will inform the DMC in 
the event of severe or extremely severe scores (z-scores 
≥2).94 The DMC will function independently of the spon-
sors and funders and will oversee and safeguard all trial 
participant interests, monitoring the overall conduct of 
the trial and ensuring the safety of patients by system-
atically checking negative events and reacting to any 
extreme distress or risk in a participant. In the case of 
an adverse event emergency, patients will be contacted 
and encouraged to receive additional help, which will be 
provided by their corresponding mental health service. 
Events will be registered/analysed by the DMC to deter-
mine whether they are adverse reactions likely associated 
with the treatment95 and whether it is advisable to leave 
treatment early. Interim analyses are not contemplated in 
the present study, although the DMC could request them 
if considered necessary for proper conducting of the trial 
and/or patient safety.
dIsCussIon
To the best of our knowledge, this Spanish RCT is the 
first to directly compare the effectiveness of a protocol 
based on compassion, such as ABCT, with an MBI, as is 
the case of the adapted MBSR, in patients suffering from 
depressive and/or anxious or adjustment disorder with 
depressive and/or anxious symptomatology in mental 
health settings. One limitation is that the absence of the 
full-day silent retreat from the MBSR intervention, and 
its derived reduction of total in-class contact, might affect 
the generalisation of the results. However, at the same 
time, this adaptation might facilitate completion of the 
programme, while balancing the intensity of both ABCT 
and MBSR interventions, making them more comparable 
by matching their application conditions. In addition, all 
the measurements considered will be self-reported; thus, 
they will be limited to that type of response. Nevertheless, 
the results of this study will provide descriptive data that 
will serve as a reference to drive future research. As we 
have already mentioned, this study will only be statistically 
powered to detect the expected large range of differences 
between groups; thus, small size differences might not 
show significant effects. However, ES estimation from a 
direct comparison between the ABCT and MBSR inter-
ventions is an area of uncertainty that must be addressed 
before developing larger studies using more compre-
hensive and more complex designs. On the other hand, 
this study will allow us to perform mediating analyses 
of possible mechanisms of change in ABCT and MBSR 
group treatments and perform a cost-effectiveness study 
of these programmes when treating depressive and/
or anxious or adjustment disorders, which are the most 
prevalent disorders among mental health outpatients 
in Spain.96 This point is of great interest because the 
Spanish healthcare system generally suffers from a scar-
city of resources, such as insufficient length of time spent 
with each patient and a disproportionate care-providing 
load. Thus, the demand for care in the Spanish mental 
health setting does not allow correct implementation 
of the evidence-based psychotherapeutic treatments of 
choice that are recommended by the clinical guidelines 
of reference in terms of duration and periodicity, which 
might cause a tendency to prescribe medication when not 
entirely indicated.97 98
The lack of funding with which to tackle mental health 
problems in Spain—which is below the level found in 
most western European countries—produces both inef-
ficient and inequitable results not only due to the scarce 
use of group psychological interventions that could 
bring beneficial solutions to the Spanish health service 
given the high burden of mental health diseases, but also 
because of the unequal effect the absence of sufficient 
resources has on poor people.99 How scarce resources are 
being used is of great importance, and economic evalua-
tions could help to improve decision-making processes. 
Thus, cost-effective group interventions aimed at treating 
mild to moderate depressive and/or anxiety or adjust-
ment psychopathological symptoms may be an appro-
priate solution to reduce the healthcare burden in the 
Spanish mental health units.
Compassion training might be considered a ‘portable 
therapy’ insofar as it is a self-to-self relationship that 
mimics the compassionate self-to-other relationship of 
psychotherapy, providing inner strength between sessions 
and, one hopes, tools for the rest of one’s life.42 However, 
due to the state of the art, whether training compassion 
in mental health units could make a difference in how 
we understand psychotherapy is a question that requires 
more evidence. Mindfulness meditation is being increas-
ingly incorporated into mental health programmes, but 
the compassion construct has not thus far been consis-
tently integrated into widely adopted MBIs.100 Results of 
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the present study will add relevant information in this 
respect.
Ethics and dissemination
All the procedures performed in this study involving 
human participants will be conducted in accordance with 
the ethical standards of the 1964 Declaration of Helsinki 
and its later amendments, the Declaration of Madrid of 
the World Psychiatric Association and the established 
requirements for manuscripts submitted to biomedical 
journals or comparable ethical standards of good clinical 
practice.
Possible protocol modifications will be decided by 
the entire research group in consultation with the DMC 
and will require prior ethics committee and trial registry 
approvals. Patients who met the inclusion criteria will 
individually receive a written general overview of the 
aims and characteristics of the study and interventions 
by the assessors, who will have sufficient time to answer 
questions and resolve possible doubts raised to ensure 
informed consent. Patients will be specifically informed 
that they will be participating voluntarily and that they 
can choose to withdraw at any time with a guarantee that 
they will continue to receive the treatment considered 
most appropriate by their specialist. After personally 
informing participants, written informed consent will be 
obtained from all the participants before they are made 
aware of the group to which they are to be allocated (an 
example of the model consent form given to participants 
is available as online supplementary file 1). For ethical 
reasons, patients allocated to ‘TAU alone’ will also be 
offered the possibility to take part in an adaptation of the 
mindfulness and compassion programmes at the end of 
the study after the 6-month follow-up measurement.
Participants’ personal information will be stored on a 
computer server at the research group’s headquarters 
and will be treated in accordance with current EU and 
Spanish legislation on privacy and data protection. To 
protect the privacy of participants, all personally identifi-
able information will be replaced by a randomly assigned 
username; original data will only be made available to 
the data manager, who will be the researcher responsible 
for its supervision. The statistician will be excluded from 
any information that could facilitate the identification of 
participants with their corresponding arm throughout 
the trial. An anonymised and blind-to-arm allocation data-
base copy will be made for use by the statistician, who will 
conduct the initial primary analysis and, after presenting 
the corresponding report, the remainder of the analyses. 
Adverse events and negative side effects will be confiden-
tial and only personally identifiable by the data manager 
and DMC.
All the findings obtained in this study will be submitted 
to high-impact peer-review journals in the field, and 
publication authorships will be based on the general 
recommendations for the conduct, reporting, editing 
and publication of scholarly work in medical journals.101 
Study participants will receive a brief personal and 
comprehensive report on request after the trial conclu-
sion by email. The protocol will be available after its 
publication. Anonymised participant-level datasets and 
procedures will be available for replication studies on 
reasonable request.
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